Curanex Pharmaceuticals Inc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CURX Nasdaq 2830 www.curanexpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Curanex Pharmaceuticals Inc

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission - May 14th, 2026 6:53 am
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline - Apr 8th, 2026 5:47 am
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care - Apr 6th, 2026 7:17 am
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company - Apr 2nd, 2026 6:07 am
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission - Mar 30th, 2026 3:35 pm
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission - Mar 18th, 2026 6:00 am
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers - Mar 12th, 2026 7:30 am
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board - Mar 11th, 2026 6:00 am
Curanex Forms World Class Scientific Advisory Board - Mar 5th, 2026 6:00 am
Curanex Provides Operational Update on Key Regulatory Milestones - Feb 25th, 2026 6:00 am
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement - Oct 22nd, 2025 5:00 am
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters - Sep 12th, 2025 12:46 pm
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering - Aug 27th, 2025 3:00 pm
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering - Aug 26th, 2025 5:30 am